Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
06/29/2000 | WO2000037094A2 Therapeutic applications of flint polypeptides |
06/29/2000 | WO2000037093A1 Bone resorption inhibitors |
06/29/2000 | WO2000037085A1 Treatment of diseases involving cyst formation |
06/29/2000 | WO2000037075A1 Combination of an at1 angiotensin ii receptor antagonist and an immunosuppressant |
06/29/2000 | WO2000037067A2 Sensitizing agents for the treatment of skin lesions |
06/29/2000 | WO2000037053A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
06/29/2000 | WO2000037052A1 Pulmonary drug delivery |
06/29/2000 | WO2000037051A1 Aerosol formulations for buccal and pulmonary application |
06/29/2000 | WO2000037022A2 Combination therapy for the treatment of sepsis |
06/29/2000 | WO2000036927A1 Method for producing granulates containing enzymes |
06/29/2000 | WO2000036920A1 Polynucleotide and polypeptide sequences of rabbit g-protein alpha 16 |
06/29/2000 | WO2000036919A1 Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues |
06/29/2000 | WO2000036918A1 Methods and compositions for treatment of cell proliferative disorders |
06/29/2000 | WO2000036910A1 Msh5 ablated mice and uses therefor |
06/29/2000 | WO2000018907A3 Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1 |
06/29/2000 | WO2000012726A3 Rationally designed heparinases derived from heparinase i and ii |
06/29/2000 | WO2000012683A3 Stem cells bearing an fgf receptor on the cell surface |
06/29/2000 | WO2000012542A3 Cytotoxic lactoferrin derivatives modified by bulky or lipophilic moieties |
06/29/2000 | WO2000012506A3 Collections of compounds |
06/29/2000 | WO2000012118A3 Inhibiting cardiomyocyte death |
06/29/2000 | WO2000012113A3 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions |
06/29/2000 | WO2000009073A3 Blood-brain barrier therapeutics |
06/29/2000 | WO2000008155A3 Human receptor-associated proteins |
06/29/2000 | WO2000008145A3 Novel genes in control of hematopoiesis |
06/29/2000 | WO2000006605A3 Heterominibodies |
06/29/2000 | WO2000001817A3 Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods |
06/29/2000 | WO2000000610A3 Human signal peptide-containing proteins |
06/29/2000 | WO2000000594A3 Human transferases |
06/29/2000 | WO1999066909A3 Method and compositions for the treatment or amelioration of female sexual dysfunction |
06/29/2000 | WO1999064034A9 β2-ADRENERGIC RECEPTOR AGONISTS |
06/29/2000 | WO1999062945A3 Peptide antigens for detection of hiv, hcv and other microbial infections |
06/29/2000 | WO1999055854A3 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth |
06/29/2000 | WO1999049019A3 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
06/29/2000 | WO1999003881A3 Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest |
06/29/2000 | WO1998059034A3 Treponema pallidum polynucleotides and sequences |
06/29/2000 | DE19954305A1 Peptide des AT¶1¶-Rezeptors und ihre Verwendung, insbesondere für die Diagnostider Präeklampsie Peptides of AT¶1¶ receptor and their use, in particular for pre-eclampsia Diagnostider |
06/29/2000 | DE19860541A1 Composition for the treatment of vascular disease comprises holozyme with hyaluronate lyase activity from microbial origin |
06/29/2000 | DE19859910A1 Cyclosporin-Lösung Cyclosporin solution |
06/29/2000 | DE19859780A1 Mittel zur Inhibition der Gewebsneubildung Means for inhibiting the formation of tissue |
06/29/2000 | DE19859385A1 Verfahren zur Herstellung von enzymhaltigen Granulaten A process for producing enzyme-containing granules |
06/29/2000 | CA2450402A1 Methods and compositions for inhibiting cancer cell growth comprising pro224 |
06/29/2000 | CA2371289A1 Novel polypeptides and nucleic acids encoding same |
06/29/2000 | CA2359586A1 Orally immunogenic bacterial enterotoxins expressed in transgenic plants |
06/29/2000 | CA2358508A1 Therapeutic applications of flint polypeptides |
06/29/2000 | CA2358492A1 Combination therapy for the treatment of sepsis |
06/29/2000 | CA2357413A1 Sensitizing agents for the treatment of skin lesions |
06/29/2000 | CA2356987A1 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
06/29/2000 | CA2356765A1 Bone resorption inhibitors |
06/29/2000 | CA2356426A1 Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia |
06/29/2000 | CA2356244A1 Somatic cells with ablated prp gene and methods of use |
06/29/2000 | CA2356010A1 Treatment of hepatitis c virus infections with interleukin-10 |
06/29/2000 | CA2355968A1 Novel protein and dna thereof |
06/29/2000 | CA2355876A1 Chlamydia trachomatis antigens |
06/29/2000 | CA2355874A1 .alpha.v.beta.6 integrin inhibitors |
06/29/2000 | CA2355836A1 Genetic suppressor elements against human immunodeficiency virus |
06/29/2000 | CA2355631A1 Msh5 ablated mice and uses therefor |
06/29/2000 | CA2355630A1 Compounds useful in the treatment of inflammatory diseases |
06/29/2000 | CA2355364A1 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
06/29/2000 | CA2355228A1 Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues |
06/29/2000 | CA2355163A1 Three dimensional structure of a sterile alpha motif domain |
06/29/2000 | CA2355074A1 Lymphocytic membrane proteins |
06/29/2000 | CA2354846A1 Method of enhancing the biological activity of ligands |
06/29/2000 | CA2354843A1 Outer surface proteins, their genes, and their use |
06/29/2000 | CA2354536A1 Ribavirin-pegylated interferon alfa induction hcv combination therapy |
06/29/2000 | CA2354369A1 Complementary dna's encoding proteins with signal peptides |
06/29/2000 | CA2354074A1 Method of identifying a psychotropic agent using differential gene expression |
06/29/2000 | CA2354030A1 Micromonospora echinospora genes encoding for biosynthesis of calicheamicin and self-resistance thereto |
06/29/2000 | CA2353848A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
06/29/2000 | CA2353799A1 Methods and compositions for inhibiting neoplastic cell growth |
06/29/2000 | CA2353790A1 Non-viral transfection vector |
06/29/2000 | CA2353775A1 Compositions and methods for the treatment of tumor |
06/29/2000 | CA2353635A1 Anilide derivative, production and use thereof |
06/29/2000 | CA2352535A1 Method for preparing suspension of stable posiplexes |
06/29/2000 | CA2346960A1 Diagnostic and therapeutics for sepsis |
06/28/2000 | EP1013772A1 Method for preparing suspension of stable posiplexes |
06/28/2000 | EP1013770A1 Non-viral transfection vector |
06/28/2000 | EP1013764A1 Immunomodulators |
06/28/2000 | EP1013763A1 CANINE INTERLEUKIN 18, CANINE INTERLEUKIN 1$g(b) CONVERTASE, DNA SEQUENCES ENCODING THE SAME, PROCESS FOR PRODUCING INTERLE UKIN 18, AND REMEDIES FOR CANINE IMMUNOLOGICAL DISEASES |
06/28/2000 | EP1013762A2 Delta-like gene expressed in neuroendocrine tumors |
06/28/2000 | EP1013761A2 Humanized chimeric antibody directed against ganglioside GD3 |
06/28/2000 | EP1013760A2 Stable bactericidal/permeabilityincreasing protein products and pharmaceutical compositions containing the same |
06/28/2000 | EP1013665A1 Novel polypeptide having water channel activity and dna sequence |
06/28/2000 | EP1013664A1 Antigenic determinants for drug-specific T lymphocytes from drug-allergic patients |
06/28/2000 | EP1013288A2 Erythropoietin in the treatment of domestic and livestock animals for anemia |
06/28/2000 | EP1013287A2 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
06/28/2000 | EP1013285A2 Urokinase-type plasminogen activator receptor |
06/28/2000 | EP1013284A2 Purified forms of dnase |
06/28/2000 | EP1013283A2 Pharmaceutical and foodstuff compositions containing transferrins and antibacteral agents for potentiating host defence activity and the treatment of infections |
06/28/2000 | EP1013282A2 Pharmaceutical and foodstuff compositions containing transferrins and antibacteral agents for potentiating host defence activity and the treatment of infections |
06/28/2000 | EP1013281A1 hCG therapy for the treatment of breast cancer |
06/28/2000 | EP1013280A1 Skin preparations for external use |
06/28/2000 | EP1013270A2 Controlled release growth hormone containing microspheres |
06/28/2000 | EP1012603A1 Functional fragments of hiv-1 vpr protein and methods of using the same |
06/28/2000 | EP1012347A1 Determination and control of bimolecular interactions |
06/28/2000 | EP1012338A1 A tumor suppressor designated ts10q23.3 |
06/28/2000 | EP1012333A1 ISOLATION OF A NOVEL SENESCENCE-FACTOR GENE, p23 |
06/28/2000 | EP1012329A1 Diagnosis and treatment of myocardial failure |
06/28/2000 | EP1012320A2 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses |
06/28/2000 | EP1012317A2 Hypoxia inducible promoter |
06/28/2000 | EP1012313A1 INTRACELLULAR INHIBITORS OF Gq PROTEIN SIGNALING |